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Background
Metabotropic glutamate receptor 5 has been suggested by
many rodent studies to be a promising target for the
development of novel analgesic drugs. The lack of
approved compounds has prevented proof-of-concept stu-
dies in human subjects. Here we describe preclinical and
translational studies of the mGlu5 negative allosteric mod-
ulator (NAM), fenobam.
Materials and methods
Fenobam was tested for analgesic efficacy and toxicity in
mouse models. We also tested the plasma levels after oral
dosing of fenobam in healthy volunteers, and collected any
adverse events following oral dosing compared to placebo.
Results
The mGlu5 NAM Fenobam is effective in a wide variety of
preclinical pain models in mice with no evidence of the
development of analgesic tolerance on daily dosing. No
obvious toxicities were observed in mice, or in several stu-
dies in healthy human volunteers.
Conclusions
Fenobam has robust analgesic activity and shows a good
safety profile. Fenobam therefore represents a useful tool
for proof-of-concept studies in human subjects.
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